International Biopharmaceutical Company Selects OmniComm’s TrialMaster® EDC for Multi-Study Cancer Research

Article

Company News Release

FORT LAUDERDALE, Fla., Nov. 27, 2018 (GLOBE NEWSWIRE) -- An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, the biopharma company will initially use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.

TrialMaster EDC was selected as one of the pharmaceutical company’s preferred EDC systems based on the system’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important. OmniComm’s robust, state-of-the-art, compliant hosting environment was another critical factor in the selection process.

“Once again, TrialMaster EDC has been selected after a rigorous evaluation process and been found to have the best-in-class technology,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “The clever way TrialMaster has been designed offers our users an easily scalable solution across the full gamut of phases and study design in oncology.”

About OmniComm Systems, Inc. 
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com  for more information, and follow OmniComm on Twitter: @OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.

Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

 

Contact InfoKuno van der PostOmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com

 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.